Novo Nordisk stops ocedurenone CLARION-CKD trial

27 June 2024

Danish diabetes and obesity giant Novo Nordisk (NOV: N) yesterday revealed that the CLARION-CKD Phase III trial failed to meet its primary endpoint and will be stopped.

As a result, Novo Nordisk said it a will recognize an impairment loss of around 5.7 billion kroner ($816 million) related to the intangible asset ocedurenone in the second quarter of 2024. The firm’s shares closed down 2% at 1,007 kroner following the announcement.

Novo Nordisk acquired ocedurenone from Singapore company KBP Biosciences in 2023 for up to $1.3 billion. The Phase III lead indication trial CLARION-CKD, which investigated ocedurenone in patients with uncontrolled hypertension and advanced chronic kidney disease, was conducted by KBP Biosciences.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK